Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 13.49% and Operating profit at 3.26% over the last 5 years
2
With a growth in Net Profit of 259.31%, the company declared Very Positive results in Sep 25
3
With ROE of 6.23%, it has a very expensive valuation with a 3.09 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 1,693 Million (Mid Cap)
50.00
NA
0.00%
-0.47
6.20%
1.04
Revenue and Profits:
Net Sales:
160 Million
(Quarterly Results - Sep 2025)
Net Profit:
32 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-9.03%
0%
-9.03%
6 Months
4.68%
0%
4.68%
1 Year
6.79%
0%
6.79%
2 Years
16.06%
0%
16.06%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Hangzhou Minsheng Healthcare Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
13.49%
EBIT Growth (5y)
3.26%
EBIT to Interest (avg)
77.15
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.58
Sales to Capital Employed (avg)
0.45
Tax Ratio
13.93%
Dividend Payout Ratio
38.82%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
11.02%
ROE (avg)
5.83%
Valuation key factors
Factor
Value
P/E Ratio
50
Industry P/E
Price to Book Value
3.09
EV to EBIT
46.06
EV to EBITDA
34.59
EV to Capital Employed
8.60
EV to Sales
5.34
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
18.67%
ROE (Latest)
6.23%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY
Sep'25
Sep'24
Change(%)
Net Sales
160.20
122.40
30.88%
Operating Profit (PBDIT) excl Other Income
4.60
5.50
-16.36%
Interest
0.00
0.00
Exceptional Items
27.20
3.00
806.67%
Consolidate Net Profit
32.50
8.90
265.17%
Operating Profit Margin (Excl OI)
28.90%
-4.60%
3.35%
USD in Million.
Net Sales
YoY Growth in quarter ended Sep 2025 is 30.88% vs 3.64% in Sep 2024
Consolidated Net Profit
YoY Growth in quarter ended Sep 2025 is 265.17% vs -23.28% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
636.00
577.50
10.13%
Operating Profit (PBDIT) excl Other Income
98.40
106.70
-7.78%
Interest
0.10
0.20
-50.00%
Exceptional Items
-0.50
1.10
-145.45%
Consolidate Net Profit
91.80
85.60
7.24%
Operating Profit Margin (Excl OI)
116.70%
136.70%
-2.00%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 10.13% vs 6.45% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 7.24% vs 8.35% in Dec 2023
About Hangzhou Minsheng Healthcare Co., Ltd. 
Hangzhou Minsheng Healthcare Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






